Milestone Pharmaceuticals Inc.
MIST
$1.69
-$0.03-1.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 127.37% | 0.72% | -34.56% | -12.38% | 9.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.90% | -10.52% | -37.40% | -41.21% | -36.52% |
| Operating Income | -95.90% | 10.52% | 37.40% | 41.21% | 32.42% |
| Income Before Tax | -100.51% | 9.17% | 37.41% | 41.64% | 30.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.51% | 9.17% | 37.41% | 41.64% | 30.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.51% | 9.17% | 37.41% | 41.64% | 30.74% |
| EBIT | -95.90% | 10.52% | 37.40% | 41.21% | 32.42% |
| EBITDA | -96.17% | 10.54% | 37.46% | 41.29% | 32.52% |
| EPS Basic | -51.74% | 41.00% | 59.36% | 62.13% | 40.84% |
| Normalized Basic EPS | -51.78% | 40.99% | 59.37% | 62.14% | 40.83% |
| EPS Diluted | -51.74% | 41.00% | 59.36% | 62.13% | 40.84% |
| Normalized Diluted EPS | -51.78% | 40.99% | 59.37% | 62.14% | 40.83% |
| Average Basic Shares Outstanding | 32.16% | 53.90% | 54.03% | 54.10% | 17.04% |
| Average Diluted Shares Outstanding | 32.16% | 53.90% | 54.03% | 54.10% | 17.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |